Regulatory progress for govorestat (AT-007) for the treatment of Classic Galactosemia, with potential NDA submission based on discussions with the…
Fiscal Q1 2024 revenue reflects a 37% increase over fiscal Q1 2023, demonstrating strong revenue growth and continued overall performanceManagement…
Since Mid-July Launch into Aggressive Expansion Phase, Company Adds Five New U.S. Distributors and Secures Initial Market-Seeding Orders for Over…
PHOENIX, AZ / ACCESSWIRE / August 9, 2023 / The Stock Day Podcast welcomed MIRA Pharmaceuticals, Inc.(Nasdaq:MIRA) ("the Company"), a…
Landmark Phase 1a/2b clinical trial of NVG-291 proceeds with recruitment of individuals with spinal cord injury; results expected in mid-2024…
Funding for Phase 1, 2, and 3 trials sought to develop NP-300 to increase American preparedness and response time in…
The Collaboration Signals Era of New Innovation for AI Nose Technology for Broader Industry AdoptionWith Partnership, Ainos Makes Progress Towards…
Estimated cash runway now extended through Q1 2026NEWARK, CA / ACCESSWIRE / August 9, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist"…
Financials for First Quarter Fiscal Year 2024 Ended June 30, 2023 will be released on August 14, 2023NORTHVALE, NJ /…
Glen Rock, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC. Pink Market: RSPI) (“RespireRx”), focused on the…